164 research outputs found
Effects of the mutations Ala30 to Pro and Ala53 to Thr on the physical and morphological properties of Ī±-synuclein protein implicated in Parkinson's disease
AbstractĪ±-Synuclein (Ī±-syn) protein has been found in association with the pathological lesions of a number of neurodegenerative diseases. Recently, mutations in the Ī±-syn gene have been reported in families susceptible to an inherited form of Parkinson's disease. We report here that human wild-type Ī±-syn, PD-linked mutant Ī±-syn(Ala30Pro) and mutant Ī±-syn(Ala53Thr) proteins can self-aggregate and form amyloid-like filaments. The mutant Ī±-syn forms more Ī²-sheet and mature filaments than the wild-type protein. These findings suggest that accumulation of Ī±-syn as insoluble deposits of amyloid may play a major role in the pathogenesis of these neurodegenerative diseases
Expansion of the Parkinson disease-associated SNCA-Rep1 allele upregulates human alpha-synuclein in transgenic mouse brain.
Alpha-synuclein (SNCA) gene has been implicated in the development of rare forms of familial Parkinson disease (PD). Recently, it was shown that an increase in SNCA copy numbers leads to elevated levels of wild-type SNCA-mRNA and protein and is sufficient to cause early-onset, familial PD. A critical question concerning the molecular pathogenesis of PD is what contributory role, if any, is played by the SNCA gene in sporadic PD. The expansion of SNCA-Rep1, an upstream, polymorphic microsatellite of the SNCA gene, is associated with elevated risk for sporadic PD. However, whether SNCA-Rep1 is the causal variant and the underlying mechanism with which its effect is mediated by remained elusive. We report here the effects of three distinct SNCA-Rep1 variants in the brains of 72 mice transgenic for the entire human SNCA locus. Human SNCA-mRNA and protein levels were increased 1.7- and 1.25-fold, respectively, in homozygotes for the expanded, PD risk-conferring allele compared with homozygotes for the shorter, protective allele. When adjusting for the total SNCA-protein concentration (endogenous mouse and transgenic human) expressed in each brain, the expanded risk allele contributed 2.6-fold more to the SNCA steady-state than the shorter allele. Furthermore, targeted deletion of Rep1 resulted in the lowest human SNCA-mRNA and protein concentrations in murine brain. In contrast, the Rep1 effect was not observed in blood lysates from the same mice. These results demonstrate that Rep1 regulates human SNCA expression by enhancing its transcription in the adult nervous system and suggest that homozygosity for the expanded Rep1 allele may mimic locus multiplication, thereby elevating PD risk
Nigrostriatal overabundance of Ī±-synuclein leads to decreased vesicle density and deficits in dopamine release that correlate with reduced motor activity
Ī±-Synuclein (Ī±-syn) is a presynaptic protein present at most nerve terminals, but its function remains largely unknown. The familial forms of Parkinson's disease associated with multiplications of the Ī±-syn gene locus indicate that overabundance of this protein might have a detrimental effect on dopaminergic transmission. To investigate this hypothesis, we use adeno-associated viral (AAV) vectors to overexpress human Ī±-syn in the rat substantia nigra. Moderate overexpression of either wild-type (WT) or A30P Ī±-syn differs in the motor phenotypes induced, with only the WT form generating hemiparkinsonian impairments. Wild-type Ī±-syn causes a reduction of dopamine release in the striatum that exceeds the loss of dopaminergic neurons, axonal fibers, and the reduction in total dopamine. At the ultrastructural level, the reduced dopamine release corresponds to a decreased density of dopaminergic vesicles and synaptic contacts in striatal terminals. Interestingly, the membrane-binding-deficient A30P mutant does neither notably reduce dopamine release nor it cause ultrastructural changes in dopaminergic axons, showing that Ī±-syn's membrane-binding properties are critically involved in the presynaptic defects. To further determine if the affinity of the protein for membranes determines the extent of motor defects, we compare three forms of Ī±-syn in conditions leading to pronounced degeneration. While membrane-binding Ī±-syns (wild-type and A53T) induce severe motor impairments, an N-terminal deleted form with attenuated affinity for membranes is inefficient in inducing motor defects. Overall, these results demonstrate that Ī±-syn overabundance is detrimental to dopamine neurotransmission at early stages of the degeneration of nigrostriatal dopaminergic axon
Cerebrospinal fluid Ī±-synuclein species in cognitive and movements disorders
Total CSF Ī±-synuclein (t-Ī±-syn), phosphorylated Ī±-syn (pS129-Ī±-syn) and Ī±-syn oligomers (o-Ī±-syn) have been studied as candidate biomarkers for synucleinopathies, with suboptimal specificity and sensitivity in the differentiation from healthy controls. Studies of Ī±-syn species in patients with other underlying pathologies are lacking. The aim of this study was to investigate possible alterations in CSF Ī±-syn species in a cohort of patients with diverse underlying pathologies. A total of 135 patients were included, comprising Parkinsonās disease (PD; n = 13), multiple system atrophy (MSA; n = 9), progressive supranuclear palsy (PSP; n = 13), corticobasal degeneration (CBD; n = 9), Alzheimerās disease (AD; n = 51), frontotemporal degeneration (FTD; n = 26) and vascular dementia patients (VD; n = 14). PD patients exhibited higher pS129-Ī±-syn/Ī±-syn ratios compared to FTD (p = 0.045), after exclusion of samples with CSF blood contamination. When comparing movement disorders (i.e., MSA vs. PD vs. PSP vs. CBD), MSA patients had lower Ī±-syn levels compared to CBD (p = 0.024). Patients with a synucleinopathy (PD and MSA) exhibited lower t-Ī±-syn levels (p = 0.002; cut-off value: ā¤865 pg/mL; sensitivity: 95%, specificity: 69%) and higher pS129-/t-Ī±-syn ratios (p = 0.020; cut-off value: ā„0.122; sensitivity: 71%, specificity: 77%) compared to patients with tauopathies (PSP and CBD). There are no significant Ī±-syn species alterations in non-synucleinopathies.This study was supported by Strat-up Funding to OE from Qatar Biomedical Research Institute (SF 2007ā007) and Qatar National Research Fund (NPRPNo.: 8ā517ā3-112)
Inhibition of alpha-synuclein seeded fibril formation and toxicity by herbal medicinal extracts.
Recent studies indicated that seeded fibril formation and toxicity of Ī±-synuclein (Ī±-syn) play a main role in the pathogenesis of certain diseases including Parkinson's disease (PD), multiple system atrophy, and dementia with Lewy bodies. Therefore, examination of compounds that abolish the process of seeding is considered a key step towards therapy of several synucleinopathies. Using biophysical, biochemical and cell-culture-based assays, assessment of eleven compounds, extracted from Chinese medicinal herbs, was performed in this study for their effect on Ī±-syn fibril formation and toxicity caused by the seeding process. Salvianolic acid B and dihydromyricetin were the two compounds that strongly inhibited the fibril growth and neurotoxicity of Ī±-syn. In an in-vitro cell model, these compounds decreased the insoluble phosphorylated Ī±-syn and aggregation. Also, in primary neuronal cells, these compounds showed a reduction in Ī±-syn aggregates. Both compounds inhibited the seeded fibril growth with dihydromyricetin having the ability to disaggregate preformed Ī±-syn fibrils. In order to investigate the inhibitory mechanisms of these two compounds towards fibril formation, we demonstrated that salvianolic acid B binds predominantly to monomers, while dihydromyricetin binds to oligomeric species and to a lower extent to monomers. Remarkably, these two compounds stabilized the soluble non-toxic oligomers lacking Ī²-sheet content after subjecting them to proteinase K digestion. Eleven compounds were tested but only two showed inhibition of Ī±-syn aggregation, seeded fibril formation and toxicity in vitro. These findings highlight an essential beginning for development of new molecules in the field of synucleinopathies treatment.The work conducted by Dr. El-Agnaf laboratory was supported by Qatar Biomedical Research Institute under the Start-up Fund SF 2017ā007. Funding for this work was provided in part by NIH/NIA grant R37AG019391 to D.E. This study was made possible by NPRP grant 4ā1371ā1-223 from the Qatar National Research Fund (a member of Qatar Foundation). The funding bodies provided financial support for this study; they had no role in the study design, performance, data collection and analysis, decision to publish and preparation/writing of the manuscript
Prion-like Ī±-synuclein pathology in the brain of infants with Krabbe disease
Krabbe disease is an infantile neurodegenerative disorder resulting from pathogenic variants in the GALC gene that causes accumulation of the toxic sphingolipid psychosine. GALC variants are also associated with Lewy body diseases, an umbrella term for age-associated neurodegenerative diseases in which the protein Ī±-synuclein aggregates into Lewy bodies. To explore whether Ī±-synuclein in Krabbe disease has pathological similarities to that in Lewy body disease, we performed an observational post-mortem study of Krabbe disease brain tissue (n = 4) compared to infant controls (n = 4) and identified widespread accumulations of Ī±-synuclein. To determine whether Ī±-synuclein in Krabbe disease brain displayed disease-associated pathogenic properties we evaluated its seeding capacity using the real-time quaking-induced conversion assay in two cases for which frozen tissue was available and strikingly identified aggregation into fibrils similar to those observed in Lewy body disease, confirming the prion-like capacity of Krabbe disease-derived Ī±-synuclein. These observations constitute the first report of prion-like Ī±-synuclein in the brain tissue of infants and challenge the putative view that Ī±-synuclein pathology is merely an age-associated phenomenon, instead suggesting it results from alterations to biological pathways, such as sphingolipid metabolism. Our findings have important implications for understanding the mechanisms underlying Lewy body formation in Lewy body disease
Nigrostriatal overabundance of alpha-synuclein leads to decreased vesicle density and deficits in dopamine release that correlate with reduced motor activity
alpha-Synuclein (alpha-syn) is a presynaptic protein present at most nerve terminals, but its function remains largely unknown. The familial forms of Parkinson's disease associated with multiplications of the alpha-syn gene locus indicate that overabundance of this protein might have a detrimental effect on dopaminergic transmission. To investigate this hypothesis, we use adeno-associated viral (AAV) vectors to overexpress human alpha-syn in the rat substantia nigra. Moderate overexpression of either wild-type (WT) or A30P alpha-syn differs in the motor phenotypes induced, with only the WT form generating hemiparkinsonian impairments. Wild-type alpha-syn causes a reduction of dopamine release in the striatum that exceeds the loss of dopaminergic neurons, axonal fibers, and the reduction in total dopamine. At the ultrastructural level, the reduced dopamine release corresponds to a decreased density of dopaminergic vesicles and synaptic contacts in striatal terminals. Interestingly, the membrane-binding-deficient A30P mutant does neither notably reduce dopamine release nor it cause ultrastructural changes in dopaminergic axons, showing that alpha-syn's membrane-binding properties are critically involved in the presynaptic defects. To further determine if the affinity of the protein for membranes determines the extent of motor defects, we compare three forms of alpha-syn in conditions leading to pronounced degeneration. While membrane-binding alpha-syns (wild-type and A53T) induce severe motor impairments, an N-terminal deleted form with attenuated affinity for membranes is inefficient in inducing motor defects. Overall, these results demonstrate that alpha-syn overabundance is detrimental to dopamine neurotransmission at early stages of the degeneration of nigrostriatal dopaminergic axons
Cerebrospinal Ī±-Synuclein Oligomers Reflect Disease Motor Severity in DeNoPa Longitudinal Cohort
Background: Tangible efforts have been made to identify biomarkers for Parkinson's disease (PD) diagnosis and progression, with Ī±-synuclein (Ī±-syn) related biomarkers being at the forefront. Objectives: The objectives of this study were to explore whether cerebrospinal fluid (CSF) levels of total, oligomeric, phosphorylated Ser 129 Ī±-synuclein, along with total tau, phosphorylated tau 181, and Ī²-amyloid 1ā42 are (1) informative as diagnostic markers for PD, (2) changed over disease progression, and/or (3) correlated with motor and cognitive indices of disease progression in the longitudinal De Novo Parkinson cohort. Methods: A total of 94 de novo PD patients and 52 controls at baseline and 24- and 48-month follow-up were included, all of whom had longitudinal lumbar punctures and clinical assessments for both cognitive and motor functions. Using our in-house enzymelinked immunosorbent assays and commercially available assays, different forms of Ī±-synuclein, tau, and Ī²-amyloid 1ā42 were quantified in CSF samples from the De Novo Parkinson cohort. Results: Baseline CSF total Ī±-synuclein was significantly lower in early de novo PD compared with healthy controls, whereas the ratio of oligomeric/total and phosphorylated/total were significantly higher in the PD group. CSF oligomeric-Ī±-synuclein longitudinally increased over the 4-year follow-up in the PD group and correlated with PD motor progression. Patients at advanced stages of PD presented with elevated CSF oligomeric-Ī±-synuclein levels compared with healthy controls. Conclusions: Longitudinal transitions of CSF biomarkers over disease progression might not occur linearly and are susceptible to disease state. CSF oligomeric-Ī±-synuclein levels appear to increase with diseases severity and reflect PD motor rather than cognitive trajectories. Ā© 2021 The Authors. Movement Disorders published by Wiley Periodicals LLC on behalf of International Parkinson and Movement Disorder Society
Fibrillar form of Ī±-synuclein-specific scFv antibody inhibits Ī±-synuclein seeds induced aggregation and toxicity
Synucleinopathies including Parkinsonās disease (PD), dementia with Lewy bodies (DLB), and multiple system atrophy (MSA) are characterized by pathological accumulation of Ī±-synuclein (Ī±-syn). Amongst the various approaches attempting to tackle the pathological features of synucleinopathies, antibody-based immunotherapy holds much promise. However, the large size of antibodies and corresponding difficulty in crossing the blood-brainĀ barrier has limited development in this area. To overcome this issue, we engineered single-chain variable fragments (scFvs) against fibrillar Ī±-syn, a putative disease-relevant form of Ī±-syn. The purified scFvs showed specific activity towards Ī±-syn fibrils and oligomers in comparison to monomers and recognized intracellular inclusions in human post-mortem brain tissue of Lewy body disease cases, but not aged controls. In vitro studies indicated scFvs inhibit the seeding of Ī±-syn aggregation in a time-dependent manner, decreased Ī±-syn seed-induced toxicity in a cell model of PD, and reduced the production of insoluble Ī±-syn phosphorylated at Ser-129 (pS129-Ī±-syn). These results suggest that our Ī±-syn fibril-specific scFvs recognize Ī±-syn pathology and can inhibit the aggregation of Ī±-syn in vitro and prevent seeding-dependent toxicity. Therefore, the scFvs described here have considerable potential to be utilized towards immunotherapy in synucleinopathies and may also have applications in ante-mortem imaging modalities.Dr. El-Agnafās laboratory was funded by Qatar Biomedical Research Institute under the Start-up Fund SF 2017ā 007. The Newcastle Brain Tissue Resource is funded in part by a grant from the UK Medical Research Council, by NIHR Newcastle Biomedical Research Centre awarded to the Newcastle upon Tyne NHS Foundation Trust and Newcastle University, and by a grant from the Alzheimerās Society and Alzheimerās Research UK as part of the Brains for Dementia Research Project
Oligomeric and phosphorylated alpha-synuclein as potential CSF biomarkers for Parkinsonās disease
- ā¦